Consequently, disrupting ECS activity through CB1R blockadehas been proposed as a potential approach to mitigate obesity-inducedhepatic steatosis and enhance systemic metabolism.11,15−17,19,20 This concept prompted pharmaceutical companies to develop CB1R-blocking drugs as possible treatments for obesity and itsassociated comorbidities. The gene discussed is CNR1; the disease is obesity disorder.